CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 154 enrolled
Drug / intervention
Olaparib +3 moredrug
Likely dose
Olaparib 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02184195
NCT02184195Phase 3Completed
CompareCT.gov

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

AstraZeneca·interventional·Posted Jul 9, 2014·Updated Sep 13, 2023

In Brief

A Phase 3 clinical trial evaluating Olaparib and Placebo for Germline BRCA1/2 Mutations and and Metastatic Adenocarcinoma of the Pancreas. Completed, enrolled 154 participants across 103 sites in 12 countries.

Detailed Summary

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGermline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
CountriesAustralia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, South Korea, Spain, United Kingdom, United States
CollaboratorsMyriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 9, 2014
Enrollment StartDec 16, 2014
Primary CompletionJan 15, 2019
Study CompletionJan 27, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.0 years ago

Interventions

Olaparibdrug

Tablet -100mg

Olaparibdrug

Tablet-150mg

Placebodrug

Match Olaparib 100mg placebo

Placebodrug

Match Olaparib 150mg placebo